Pan India Corpor (511525)
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹2.21 |
| Market Cap | ₹49.75 Cr |
| P/E Ratio | 0 |
| ROCE | -36.35% |
| ROE | -4.07% |
| Dividend Yield | 0% |
| Profit Growth | -66.67% |
| Debt/Equity | — |
| Sales Growth | 0% |
| 52-Week Range | ₹1.35 — ₹2.47 |
| Sector | Finance |
| Book Value | ₹0.65 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Let me look at Pan India Corpor with the same eyes I would use for any business. First, what does it earn? It earns nothing. Sales are zero, and the latest quarter shows a net loss of roughly ₹0 Cr. Over a year, profit growth has fallen 66.67%, ROE is -4.07% and ROCE is -36.35%. This is not a business; it is an investment entity holding assets, and those assets are not generating acceptable returns. Benjamin Graham taught me to use book value as a starting point. Here book value is ₹0.65 per share, so the ₹2.21 price means I am paying 3.4 times net assets. For that premium, I require strong profitability, a clear moat, or a catalyst. None exists. The Piotroski F-Score of 2 out of 9 is a distress signal. No dividend is coming to me as I wait. The 52-week range of ₹1.35 to ₹2.70 tells me the market is speculating, not valuing. With a market cap of ₹50 crore and no earnings, the P/E is meaningless. If I own the shares, I am relying entirely on someone else paying more. That is not investment; it is speculation. In the classic Graham framework, an asset play needs a discount to net asset value. Here I am asked to pay a 240% premium to book value for a company whose returns on capital are deeply negative. I would rather keep my cash. The only thing that would interest me is evidence of hidden assets or a credible turnaround in the underlying portfolio. Until I see that, Pan India Corpor remains a pass.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer